Explore EasyPGX® Ready

the comprehensive IVD portfolio for solid and blood cancer biomarkers.

EasyPGX® Ready combines dedicated assays for both solid and hematologic malignancies in one streamlined platform with a simplified workflow. Discover the all-in-one qPCR solution designed to advance precision medicine.

EasyPGX® Ready solid tumor portfolio

Thyroid
Cancer

KRAS, BRAF, NRAS,
RET, HRAS, PPARG

Non-Small Cell
Lung Cancer

KRAS, BRAF, EGFR,
ALK, ROS1, RET, MET

Colorectal
Cancer

KRAS, BRAF, NRAS,
MSI, MLH1, РІКЗСА

Urothelial
Cancer

FGFR2-3

Melanoma

BRAF, NRAS

Liquid Biopsy
Assays

KRAS, BRAF, EGFR,
NRAS, PIK3CA, ESR1

Pharmacogenetics

DPYD, UGT1A1

Tumour-Agnostic
Biomarkers

MSI, NTRK,
RET, BRAF

Head and
Neck Cancer

HPV, HRAS

Cholangiocarcinoma

IDH1-2, FGFR2,
KRAS, BRAF

Gynecologic
Cancers

HPV, MSI, MLH1

Breast
Cancer

РІКЗСА, ESR1

Glioma

BRAF, IDH1-2,
MGMT

Thyroid Cancer

KRAS, BRAF, NRAS, RET, HRAS, PPARG

Non-Small Cell Lung Cancer

KRAS, BRAF, EGFR, ALK, ROS1, RET, MET

Colorectal Cancer

KRAS, BRAF, NRAS, MSI, MLH1, РІКЗСА

Urothelial Cancer

FGFR2-3

Melanoma

BRAF, NRAS

Liquid Biopsy Assays

KRAS, BRAF, EGFR, NRAS, PIK3CA, ESR1

Pharmaco-genetic

DPYD, UGT1A1

Tumour-Agnostic Biomarkers

MSI, NTRK, RET, BRAF

Head and Neck Cancer

HPV, HRAS

Head and Neck Cancer

HPV, HRAS

Cholangio-carcinoma

IDH1-2, FGFR2, KRAS, BRAF

Gynecologic Cancers

HPV, MSI, MLH1

Breast
Cancer

РІКЗСА, ESR1

Glioma

BRAF, IDH1-2, MGMT

EasyPGX Ready Blood cancer portfolio

Diagnosis & Prognosis

BCR-ABL

AML1-ETO

CBFB-MYH11

PML-RARA

IDH1-2

NPM1

JAK 2

MRD Monitoring

BCR-ABL p210

BCR-ABL p190

NPM1

WT1

JAK 2

You are leaving this research use-only area

You are about to access content intended for a different region. Information, regulatory status, and product availability may vary by location.

Do you wish to continue?

Select Your Region

Please select your region to access the content that is most relevant to your location and applicable regulations.